U.S. markets closed

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.30000.0000 (0.00%)
At close: 1:45PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3000
Open1.3000
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range1.3000 - 1.3000
52 Week Range0.7000 - 2.1600
Volume512
Avg. Volume13,393
Market Cap63.683M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.0890
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Emmaus Life Sciences Provides Form 10-K Filing Update
    PR Newswire

    Emmaus Life Sciences Provides Form 10-K Filing Update

    Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its Audit Committee will meet the week of April 19 to review and approve the filing of the company's 2020 Annual Report on Form 10-K and related earnings release. Due to the additional time required to complete the auditors' review process, Emmaus will be unable to file its 2020 Form 10-K with the Securities and Exchange Commission ("SEC") by April 15, 2021 as previously indicated in the company's Form NT 10-K filed with the SEC on March 31, 2021. Emmaus expects to issue a press release on the company's 2020 operating results and file its 2020 Form 10-K shortly following the Audit Committee meeting.

  • Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug
    PR Newswire

    Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug

    Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that it has entered into an agreement with Kainos Medicine, Inc. ("Kainos") to lead the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug and further advance the research and development activity currently underway at Kainos. With this agreement in place, Kainos plans to complete the study of the therapeutic mechanism of action ("MOA") of KM10544 in solid cancers, blood cancers and lymphoma. Emmaus will be responsible for the investigation and proof of target disease selection, efficacy and safety. In a related development, the companies also entered into a letter of intent regarding possible future joint development of small molecule therapeutics and other pharmaceutical assets.

  • Emmaus Life Sciences Reports Increase in Sales Volume in 2020
    PR Newswire

    Emmaus Life Sciences Reports Increase in Sales Volume in 2020

    Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%. Emmaus is providing this information in advance of the filing of its Quarterly Reports on Form 10-Q for the first, second and third quarters of 2020 and Annual Report on Form 10-K for the year ended December 31, 2020.